inclusion criteria: * participants who have a positive sars-cov-2 test result. * participants who have one or more mild or moderate covid-19 symptoms, and total symptom score ≥ 2. * participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to the first dose; ≤5 days from the first onset of covid-19 symptoms to the first dose; sars-cov-2 ct value ≤20 within 24 hours prior to the first dose. * participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. * participants who must agree to adhere to contraception restrictions. * participants who understand and agree to comply with planned study procedures. * participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site. * capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: * participants who have a positive sars-cov-2 test result. * participants who have one or more mild or moderate covid-19 symptoms, and total symptom score ≥ 2. * participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to the first dose; ≤5 days from the first onset of covid-19 symptoms to the first dose; sars-cov-2 ct value ≤20 within 24 hours prior to the first dose. * participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. * participants who must agree to adhere to contraception restrictions. * participants who understand and agree to comply with planned study procedures. * participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site. * capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: participants who have a positive sars-cov-2 test result. participants who have one or more mild or moderate covid-19 symptoms, and total symptom score ≥ 2. participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to the first dose; ≤5 days from the first onset of covid-19 symptoms to the first dose; sars-cov-2 ct value ≤20 within 24 hours prior to the first dose. participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. participants who must agree to adhere to contraception restrictions. participants who understand and agree to comply with planned study procedures. participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site. capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: participants who have a positive sars-cov-2 test result. participants who have one or more mild or moderate covid-19 symptoms, and total symptom score ≥ 2. participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to the first dose; ≤5 days from the first onset of covid-19 symptoms to the first dose; sars-cov-2 ct value ≤20 within 24 hours prior to the first dose. participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. participants who must agree to adhere to contraception restrictions. participants who understand and agree to comply with planned study procedures. participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site. capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: participants who have a positive sars-cov-2 test result. participants who have one or more mild or moderate covid-19 symptoms. participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to the first dose; ≤5 days from the first onset of covid-19 symptoms to the first dose. participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. participants who must agree to adhere to contraception restrictions. participants who understand and agree to comply with planned study procedures. participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site. capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: participants who have a positive sars-cov-2 test result. participants who have one or more mild or moderate covid-19 symptoms. participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to the first dose; ≤5 days from the first onset of covid-19 symptoms to the first dose. participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. participants who must agree to adhere to contraception restrictions. participants who understand and agree to comply with planned study procedures. participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site. capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.